These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
429 related articles for article (PubMed ID: 31896808)
1. Detection of the KIT Craig JW; Hasserjian RP; Kim AS; Aster JC; Pinkus GS; Hornick JL; Steensma DP; Coleman Lindsley R; DeAngelo DJ; Morgan EA Mod Pathol; 2020 Jun; 33(6):1135-1145. PubMed ID: 31896808 [TBL] [Abstract][Full Text] [Related]
2. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Wang SA; Hutchinson L; Tang G; Chen SS; Miron PM; Huh YO; Jones DM; Bueso-Ramos C; Verstovsek S; Medeiros LJ; Miranda RN Am J Hematol; 2013 Mar; 88(3):219-24. PubMed ID: 23440662 [TBL] [Abstract][Full Text] [Related]
3. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Pullarkat VA; Bueso-Ramos C; Lai R; Kroft S; Wilson CS; Pullarkat ST; Bu X; Thein M; Lee M; Brynes RK Am J Hematol; 2003 May; 73(1):12-7. PubMed ID: 12701114 [TBL] [Abstract][Full Text] [Related]
4. Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations. Naumann N; Lübke J; Shomali W; Reiter L; Horny HP; Jawhar M; Dangelo V; Fabarius A; Metzgeroth G; Kreil S; Sotlar K; Oni C; Harrison C; Hofmann WK; Cross NCP; Valent P; Radia D; Gotlib J; Reiter A; Schwaab J Br J Haematol; 2021 Jul; 194(2):344-354. PubMed ID: 34060083 [TBL] [Abstract][Full Text] [Related]
5. High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V. Fritsche-Polanz R; Fritz M; Huber A; Sotlar K; Sperr WR; Mannhalter C; Födinger M; Valent P Mol Oncol; 2010 Aug; 4(4):335-46. PubMed ID: 20471335 [TBL] [Abstract][Full Text] [Related]
11. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Ustun C; Corless CL; Savage N; Fiskus W; Manaloor E; Heinrich MC; Lewis G; Ramalingam P; Kepten I; Jillella A; Bhalla K Leuk Res; 2009 May; 33(5):735-41. PubMed ID: 18986703 [TBL] [Abstract][Full Text] [Related]
12. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype. Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059 [TBL] [Abstract][Full Text] [Related]
13. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). Sotlar K; Colak S; Bache A; Berezowska S; Krokowski M; Bültmann B; Valent P; Horny HP J Pathol; 2010 Apr; 220(5):586-95. PubMed ID: 20112369 [TBL] [Abstract][Full Text] [Related]
14. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. Kanagal-Shamanna R; Bueso-Ramos CE; Barkoh B; Lu G; Wang S; Garcia-Manero G; Vadhan-Raj S; Hoehn D; Medeiros LJ; Yin CC Cancer; 2012 Jun; 118(11):2879-88. PubMed ID: 22038701 [TBL] [Abstract][Full Text] [Related]
15. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC). Miesner M; Haferlach C; Bacher U; Weiss T; Macijewski K; Kohlmann A; Klein HU; Dugas M; Kern W; Schnittger S; Haferlach T Blood; 2010 Oct; 116(15):2742-51. PubMed ID: 20581309 [TBL] [Abstract][Full Text] [Related]
16. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia. Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934 [TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukaemia with t(8;21) associated with "occult" mastocytosis. Report of an unusual case and review of the literature. Bernd HW; Sotlar K; Lorenzen J; Osieka R; Fabry U; Valent P; Horny HP J Clin Pathol; 2004 Mar; 57(3):324-8. PubMed ID: 14990611 [TBL] [Abstract][Full Text] [Related]
18. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. Hoermann G; Gleixner KV; Dinu GE; Kundi M; Greiner G; Wimazal F; Hadzijusufovic E; Mitterbauer G; Mannhalter C; Valent P; Sperr WR Allergy; 2014 Jun; 69(6):810-3. PubMed ID: 24750133 [TBL] [Abstract][Full Text] [Related]
19. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. Jawhar M; Schwaab J; Horny HP; Sotlar K; Naumann N; Fabarius A; Valent P; Cross NC; Hofmann WK; Metzgeroth G; Reiter A Eur J Clin Invest; 2016 May; 46(5):392-7. PubMed ID: 26914980 [TBL] [Abstract][Full Text] [Related]
20. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. Hoermann G; Sotlar K; Jawhar M; Kristensen T; Bachelot G; Nedoszytko B; Carter MC; Horny HP; Bonadonna P; Sperr WR; Hartmann K; Brockow K; Lyons JJ; Kluin-Nelemans HC; Hermine O; Akin C; Broesby-Olsen S; Triggiani M; Butterfield JH; Schwaab J; Reiter A; Gotlib J; Metcalfe DD; George TI; Orfao A; Valent P; Arock M J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1953-1963. PubMed ID: 35283331 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]